Let’s start up with the current stock price of Adamis Pharmaceuticals Corporation (ADMP), which is $0.81 to be very precise. The Stock rose vividly during the last session to $0.835 after opening rate of $0.785 while the lowest price it went was recorded $0.775 before closing at $0.79.
Adamis Pharmaceuticals Corporation had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.5100 on 07/29/20, with the lowest value was $0.2700 for the same time period, recorded on 03/18/20.
Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.
Adamis Pharmaceuticals Corporation (ADMP) full year performance was 5.61%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Adamis Pharmaceuticals Corporation shares are logging -46.50% during the 52-week period from high price, and 199.22% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.27 and $1.51.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2541571 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Adamis Pharmaceuticals Corporation (ADMP) recorded performance in the market was 15.35%, having the revenues showcasing 24.97% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 63.51M, as it employees total of 131 workers.
The Analysts eye on Adamis Pharmaceuticals Corporation (ADMP)
During the last month, 0 analysts gave the Adamis Pharmaceuticals Corporation a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.7126, with a change in the price was noted +0.4212. In a similar fashion, Adamis Pharmaceuticals Corporation posted a movement of +108.92% for the period of last 100 days, recording 4,693,632 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ADMP is recording 0.23 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.09.
Technical rundown of Adamis Pharmaceuticals Corporation (ADMP)
Raw Stochastic average of Adamis Pharmaceuticals Corporation in the period of last 50 days is set at 31.03%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 57.33%. In the last 20 days, the company’s Stochastic %K was 50.45% and its Stochastic %D was recorded 42.71%.
Considering, the past performance of Adamis Pharmaceuticals Corporation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 15.35%. Additionally, trading for the stock in the period of the last six months notably improved by 144.82%, alongside a boost of 5.61% for the period of the last 12 months. The shares increased approximately by 4.77% in the 7-day charts and went up by -14.05% in the period of the last 30 days. Common stock shares were driven by 24.97% during last recorded quarter.